X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1326) 1326
Publication (90) 90
Conference Proceeding (14) 14
Book Review (10) 10
Book Chapter (8) 8
Patent (8) 8
Book / eBook (4) 4
Dissertation (2) 2
Magazine Article (2) 2
Government Document (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (519) 519
index medicus (331) 331
oncology (313) 313
male (305) 305
female (275) 275
middle aged (242) 242
adult (203) 203
aged (196) 196
carcinoma, renal cell - drug therapy (181) 181
cancer (179) 179
kidney neoplasms - drug therapy (174) 174
kidney neoplasms - pathology (134) 134
renal cell carcinoma (130) 130
treatment outcome (127) 127
sunitinib (125) 125
interferon-alpha (102) 102
sorafenib (95) 95
antineoplastic agents - therapeutic use (94) 94
carcinoma, renal cell (94) 94
hematology, oncology and palliative medicine (92) 92
survival (92) 92
prognosis (86) 86
urology & nephrology (86) 86
disease-free survival (84) 84
carcinoma, renal cell - pathology (83) 83
care and treatment (80) 80
metastasis (80) 80
aged, 80 and over (76) 76
carcinoma, renal cell - secondary (76) 76
therapy (75) 75
bevacizumab (70) 70
neoplasm metastasis (69) 69
urology (69) 69
adolescent (66) 66
carcinoma, renal cell - mortality (63) 63
immunotherapy (63) 63
kidney neoplasms - mortality (63) 63
retrospective studies (62) 62
life sciences (59) 59
everolimus (58) 58
analysis (57) 57
antineoplastic combined chemotherapy protocols - therapeutic use (55) 55
kidney cancer (54) 54
niacinamide - analogs & derivatives (53) 53
double-blind (52) 52
nephrectomy (51) 51
targeted therapy (51) 51
research (50) 50
trial (50) 50
antineoplastic agents - adverse effects (49) 49
efficacy (48) 48
prospective studies (48) 48
kidney neoplasms - therapy (47) 47
survival analysis (46) 46
carcinoma, renal cell - therapy (44) 44
risk factors (44) 44
tumors (43) 43
medicine, general & internal (42) 42
renal-cell carcinoma (42) 42
young adult (41) 41
child (40) 40
drug therapy (40) 40
carcinoma (39) 39
follow-up studies (39) 39
vascular endothelial growth factor (39) 39
animals (38) 38
expression (38) 38
phenylurea compounds (38) 38
survival rate (38) 38
chemotherapy (37) 37
protein kinase inhibitors - therapeutic use (37) 37
time factors (37) 37
abridged index medicus (36) 36
angiogenesis (36) 36
diagnosis (36) 36
metastases (36) 36
patients (36) 36
management (35) 35
indoles - therapeutic use (34) 34
patient outcomes (34) 34
pyrroles - therapeutic use (34) 34
antineoplastic agents (33) 33
clinical trials (33) 33
sirolimus - analogs & derivatives (33) 33
endothelial growth-factor (32) 32
interleukin-2 (32) 32
mutation (32) 32
respiratory system (32) 32
angiogenesis inhibitors - therapeutic use (31) 31
antimitotic agents (31) 31
carcinoma, renal cell - genetics (30) 30
kaplan-meier estimate (30) 30
genetics & heredity (29) 29
health aspects (29) 29
medicine & public health (29) 29
immunology (28) 28
kidney neoplasms - genetics (28) 28
kidney neoplasms - surgery (28) 28
phase-ii (28) 28
phase-iii trial (28) 28
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2097 - 2107
Among patients who had had an acute coronary syndrome, the risk of death from coronary heart disease, nonfatal myocardial infarction, stroke, or unstable... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | MYOCARDIAL-INFARCTION | TASK-FORCE | EFFICACY | SAFETY | LDL | REDUCING LIPIDS | PCSK9 | MONOCLONAL-ANTIBODY | ASSOCIATION | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Acute Coronary Syndrome - complications | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Cardiovascular Diseases - epidemiology | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Acute coronary syndrome | Diagnosis | Myocardial infarction | Fees & charges | Lipoproteins (low density) | Heart attacks | Lipids | Cardiovascular disease | Angina | Apolipoprotein B | Ischemia | Heart diseases | Drug dosages | Statins | Cerebral infarction | Stroke | Subtilisin | Angina pectoris | Patients | Low density lipoprotein | Coronary artery disease | Cholesterol | Kexin | Monoclonal antibodies | Full text | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Pharmaceuticals | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1527 - 1539
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 12, pp. 1139 - 1151
Journal Article